Metropolis Healthcare Ltd. (METROPOLIS) Price & Analysis

Compare

3 Followers

METROPOLIS Stock Chart & Stats

₹1929.70

-₹8.50(-0.42%)

At close: Jan 08 4:00 PM EST

₹1929.70

-₹8.50(-0.42%)

Day’s Range― - ―

52-Week Range₹1,383.70 - ₹2,259.30

Previous CloseN/A

Volume139.28K

Average Volume (3M)3.90K

Market Cap

₹93.50B

Enterprise Value₹96.43B

Total Cash (Recent Filing)₹1.18B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)60.4

Beta0.72

Next Earnings

May 26, 2026

EPS Estimate

10.73

Next Dividend Ex-DateN/A

Dividend Yield0.21%

Share Statistics

EPS (TTM)9.25

Shares Outstanding51,831,944

10 Day Avg. Volume4,604

30 Day Avg. Volume3,901

Financial Highlights & Ratios

PEG Ratio4.05

Price to Book (P/B)5.90

Price to Sales (P/S)5.90

P/FCF Ratio35.81

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)40.53

Revenue Forecast (FY)₹16.53B

Bulls Say, Bears Say

Bulls Say

Strong Balance SheetLow leverage and a 71.3% equity ratio provide durable financial flexibility, enabling Metropolis to fund lab capacity, absorb reimbursement cycles, and pursue strategic investments without stressing cash flows. This capital structure reduces insolvency risk and supports multi-year growth plans.

Robust Cash GenerationConsistent FCF growth and high cash-to-income conversion underscore sustainable internal funding for expansion, technology and shareholder returns. Strong cash conversion lowers reliance on external financing and allows steady reinvestment into collection networks and specialized testing capabilities.

High Margins With Revenue GrowthElevated gross and operating margins reflect scalable central lab operations and pricing power in specialized testing. Combined with mid-single-digit to double-digit revenue growth, these margins support durable profitability and fund continued network and capability expansion over the medium term.

Bears Say

Moderate Return On EquityROE of ~11% is moderate given the high equity base, suggesting limited capital efficiency. Over several quarters this can constrain shareholder returns unless management improves asset utilization, margin lift, or pursues higher-return investments, which may be challenging in core diagnostics.

Modest EPS GrowthEPS growth near 9% is lower than some revenue and margin metrics, implying potential dilution, reinvestment, or margin pressures. Sustaining stronger shareholder earnings will require continued margin expansion or higher revenue mix in specialized, higher-margin tests over multiple quarters.

Revenue Model ConcentrationHeavy dependence on test-fee revenue exposes Metropolis to pricing pressure, reimbursement changes, and competition. Structural risks include regulatory rate shifts or commoditization of routine tests; durable resilience requires diversification into services, contracts, or higher-value specialties.

Metropolis Healthcare Ltd. News

Metropolis Healthcare Shareholders Approve Bonus Share Issue via E-Voting

An update from Metropolis Healthcare Ltd. ( ($IN:METROPOLIS) ) is now available. Metropolis Healthcare has secured shareholder approval...

7d ago

Metropolis Healthcare Clears Q3 FY26 Results, Announces 3:1 Bonus Issue and Internal Business Transfer

Metropolis Healthcare Ltd. ( ($IN:METROPOLIS) ) just unveiled an update. Metropolis Healthcare Limited’s board has approved the unaudited...

1M ago

Metropolis Healthcare Schedules Q3 FY26 Earnings Call for February 5

An announcement from Metropolis Healthcare Ltd. ( ($IN:METROPOLIS) ) is now available. Metropolis Healthcare Limited has announced that...

1M ago

Metropolis Healthcare to Discuss Q2 FY26 Financial Results in Upcoming Conference Call

An announcement from Metropolis Healthcare Ltd. ( ($IN:METROPOLIS) ) is now available. Metropolis Healthcare Limited has announced its...

5M ago

METROPOLIS FAQ

What was Metropolis Healthcare Ltd.’s price range in the past 12 months?

Metropolis Healthcare Ltd. lowest stock price was ₹1383.70 and its highest was ₹2259.30 in the past 12 months.

What is Metropolis Healthcare Ltd.’s market cap?

Metropolis Healthcare Ltd.’s market cap is ₹93.50B.

When is Metropolis Healthcare Ltd.’s upcoming earnings report date?

Metropolis Healthcare Ltd.’s upcoming earnings report date is May 26, 2026 which is in 71 days.

How were Metropolis Healthcare Ltd.’s earnings last quarter?

Metropolis Healthcare Ltd. released its earnings results on Feb 04, 2026. The company reported ₹9.25 earnings per share for the quarter, beating the consensus estimate of ₹8.939 by ₹0.311.

Is Metropolis Healthcare Ltd. overvalued?

According to Wall Street analysts Metropolis Healthcare Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Metropolis Healthcare Ltd. pay dividends?

Metropolis Healthcare Ltd. pays a Annually dividend of ₹4 which represents an annual dividend yield of 0.21%. See more information on Metropolis Healthcare Ltd. dividends here

What is Metropolis Healthcare Ltd.’s EPS estimate?

Metropolis Healthcare Ltd.’s EPS estimate is 10.73.

How many shares outstanding does Metropolis Healthcare Ltd. have?

Metropolis Healthcare Ltd. has 51,831,944 shares outstanding.

What happened to Metropolis Healthcare Ltd.’s price movement after its last earnings report?

Metropolis Healthcare Ltd. reported an EPS of ₹9.25 in its last earnings report, beating expectations of ₹8.939. Following the earnings report the stock price went down -0.474%.

Which hedge fund is a major shareholder of Metropolis Healthcare Ltd.?

Currently, no hedge funds are holding shares in IN:METROPOLIS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Metropolis Healthcare Ltd.

Metropolis Healthcare Limited provides diagnostic services in India. It offers clinical laboratory testing, and profiles and support services. The company provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, and youth and corporates. Its tests and profiles are used for prediction, early detection, diagnostic screening, confirmation, and/or monitoring of the disease. The company also offers corporate wellness and hospital laboratory solutions, as well as clinical research services. As of March 31, 2022, it operated 171 clinical laboratories, 9,000 pick-up points, and 704 assisted referral centers. The company was founded in 1980 and is headquartered in Mumbai, India.